BGPartner advised Novo Holdings, EQT, OrbiMed and SR One on $100 million Series C financing of Swiss biotech company Asceneuron, represented by Lenz & Staehelin, Geneva. The financing round was led by Novo Holdings with new
Tags :Asceneuron
Spanish pharmaceutical company Ferrer and Swiss clinical stage biotechnology company Asceneuron have announced the signing of a licensing agreement in which Ferrer obtains the exclusive worldwide rights to develop and commercialize ASN90 in progressive supranuclear